001360655 000__ 02821cam\\2200637\i\4500
001360655 001__ 1360655
001360655 003__ OCoLC
001360655 005__ 20210812132237.0
001360655 007__ he\bmb024bbca
001360655 008__ 181109s2018\\\\dcu\\\\\bb\\\f000\0\eng\c
001360655 019__ $$a1225640727
001360655 035__ $$a(OCoLC)1062362734
001360655 040__ $$aGPO$$beng$$erda$$cGPO$$dGPO$$dOCLCF$$dVDB$$dOCLCO$$dISE
001360655 042__ $$apcc
001360655 043__ $$an-us---
001360655 049__ $$aISEA
001360655 074__ $$a1008-D (MF)
001360655 0860_ $$aY 1.1/8:115-728
001360655 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Energy and Commerce,$$eauthor.
001360655 24510 $$aMedicaid Drug Review, Utilization, Good Governance Improvement Act :$$breport (to accompany H.R. 5799) (including cost estimate of the Congressional Budget Office).
001360655 264_1 $$a[Washington, D.C.] :$$b[U.S. Government Publishing Office],$$c[2018]
001360655 300__ $$a147 pages ;$$c24 cm.
001360655 336__ $$atext$$btxt$$2rdacontent
001360655 337__ $$amicroform$$bh$$2rdamedia
001360655 338__ $$amicrofiche$$bhe$$2rdacarrier
001360655 4901_ $$aReport / 115th Congress, 2d session, House of Representatives ;$$v115-728
001360655 500__ $$aTitle from caption.
001360655 500__ $$a"June 12, 2018."
001360655 500__ $$aShipping list no.: 2018-0192-M.
001360655 504__ $$aIncludes bibliographical references.
001360655 533__ $$aMicrofiche.$$b[Washington, D.C.] :$$cU.S. Government Printing Office,$$d[2018]$$e2 microfiches : negative.
001360655 61010 $$aUnited States.$$tSocial Security Act.
001360655 63007 $$aSocial Security Act (United States)$$2fast$$0(OCoLC)fst01356645
001360655 650_0 $$aMedicare beneficiaries$$xIdentification.
001360655 650_0 $$aDrugs$$zUnited States$$xSafety measures.
001360655 650_0 $$aMedicare fraud$$xPrevention.
001360655 650_0 $$aMedicaid fraud$$xPrevention.
001360655 650_0 $$aFraud$$xPrevention$$xGovernment policy$$zUnited States.
001360655 650_0 $$aOpioid abuse$$xTreatment$$zUnited States$$xCosts.
001360655 650_0 $$aMedicare$$xCost control.
001360655 650_0 $$aMedicare$$xLaw and legislation.
001360655 650_7 $$aDrugs$$xSafety measures.$$2fast$$0(OCoLC)fst00898909
001360655 650_7 $$aMedicaid fraud$$xPrevention.$$2fast$$0(OCoLC)fst01013690
001360655 650_7 $$aMedicare beneficiaries.$$2fast$$0(OCoLC)fst01014847
001360655 650_7 $$aMedicare$$xCost control.$$2fast$$0(OCoLC)fst01014824
001360655 650_7 $$aMedicare fraud$$xPrevention.$$2fast$$0(OCoLC)fst01014849
001360655 650_7 $$aMedicare$$xLaw and legislation.$$2fast$$0(OCoLC)fst01014839
001360655 651_7 $$aUnited States.$$2fast$$0(OCoLC)fst01204155
001360655 655_7 $$aField guides.$$2fast$$0(OCoLC)fst01940354
001360655 655_7 $$aLegislative materials.$$2fast$$0(OCoLC)fst01774285
001360655 655_7 $$aLegislative materials.$$2lcgft
001360655 77608 $$iPrint version:$$aUnited States. Congress. House. Committee on Energy and Commerce.$$tMedicaid Drug Review, Utilization, Good Governance Improvement Act$$w(OCoLC)1041708255
001360655 77608 $$iOnline version:$$aUnited States. Congress. House. Committee on Energy and Commerce.$$tMedicaid Drug Review, Utilization, Good Governance Improvement Act$$w(OCoLC)1041706883
001360655 8101_ $$aUnited States.$$bCongress.$$bHouse.$$tReport ;$$v115-728.
001360655 852__ $$bdfich
001360655 852__ $$bedoc$$hY 1.1/8:115-728
001360655 85640 $$uhttps://purl.fdlp.gov/GPO/gpo93921
001360655 909CO $$ooai:library.usi.edu:1360655$$pGLOBAL_SET
001360655 980__ $$aBIB
001360655 980__ $$aEGOV
001360655 982__ $$aGovernment E-Resource
001360655 983__ $$aOnline
001360655 994__ $$aC0$$bISE